Skip to content

Bicara Therapeutics BCAX Stock Issued During Period, Value, Stock Options Exercised

Stock Issued During Period, Value, Stock Options Exercised at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's stock issued during period, value, stock options exercised.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's stock issued during period, value, stock options exercised?
Bicara Therapeutics (BCAX) reported stock issued during period, value, stock options exercised of $1.58M in Q1 2026.
How has Bicara Therapeutics's stock issued during period, value, stock options exercised changed year-over-year?
Bicara Therapeutics's stock issued during period, value, stock options exercised increased by 231.7% year-over-year, from $477K to $1.58M.
What does stock issued during period, value, stock options exercised mean?
The cash proceeds received by the company from the exercise of employee or director stock options. This metric indicates the extent to which equity-based compensation plans are being utilized and converted into actual share ownership. It serves as a proxy for the alignment between employee incentives and shareholder interests.